-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Radiation Oncology
-
Spine Stereotactic Radiosurgery: A Critical Evaluation of the Evidence to Guide Clinical Practice
Spine metastases represent a common complication of lung cancer and other cancers, with approximately 40% of patients developing clinically significant spinal metastatic disease and up to 90% developing subclinical micrometastases. In addition to site-associated pain, spine metastases can also cause neurologic deficits, reduced mobility, and a decline in a patient’s performance status and quality of…
-
Radiotherapy Inaccessibility in Lung Cancer Care: An Ongoing Crisis
A leading cause of mortality worldwide, cancer was tied to nearly 10 million deaths in 2020.1 Lung cancer has remained unchallenged for more than 30 years as the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide, accounting for up to 1.8 million deaths per year.2 ,3 Treatment for lung cancer depends…
-
Cardiac Toxicity of Lung Cancer Radiotherapy
A 65-year-old patient with stage III NSCLC comes to your clinic to discuss concurrent chemoradiotherapy. She has a history of ischemic heart disease, and 4 years ago an angiogram demonstrated minor coronary artery disease that did not require intervention. Her angina is well-controlled on medication, and she only rarely uses her glyceryl trinitrate spray. She…
-
Hippocampal-Sparing Brain Irradiation: The Future of Brain Metastases Treatment and Prevention?
Brain metastases (BMs) are frequently diagnosed in patients with SCLC and NSCLC, although the incidence is highest in SCLC.1 ,2 ,3 BMs are a negative prognostic factor and are associated with a decreased quality of life (QoL).2 ,4 Therefore, it is important to prevent or to treat them early. Prophylactic cranial irradiation (PCI) significantly reduces…
-
Prophylactic Radiotherapy: A Case for Patients at High Risk of Brain Metastases
Prophylactic radiotherapy for the prevention of brain metastases (Table 1) has not been considered a standard practice outside of limited stage SCLC, particularly amid the surge and approval of novel targeted therapies that have shifted the outlook for patients with oncogene-addicted lung adenocarcinomas. However, a recently published randomized clinical trial is generating debate among clinicians…
-
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Con Side
The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeting, revealing a lack of benefit for…
-
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Pro Side
The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeting, revealing a lack of benefit for…
-
Deeper Dive Toxicity of Lung SBRT and Concurrent Immunotherapy Combinations: What We Know and What We Still Need to Learn
In Reference To: Tian S, Switchenko JM, Buchwald ZS, et al. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. Int J Radiat Oncol Biol Phys. 2020;108(1):304-313.
-
The Dandelion Dilemma of Brain Metastases: Treating the Whole Lawn or the Weeds Separately
Approximately, 40% to 60% of patients with small cell lung cancer (SCLC) develop brain metastases (BMs),1 ,2 ,3 and fewer than 15% survive beyond 2 years.4 ,5 Whereas upfront stereotactic radiosurgery (SRS) has become the preferred treatment for brain metastases arising from most solid tumor histologies,6 SCLC remains an exception where whole brain radiotherapy (WBRT)…
-
PET vs. CT in Lung Cancer Surveillance: The ‘Pro’ Side from the Nuclear Medicine Perspective
A significant proportion of patients with stage I to III NSCLC or SCLC will have locoregional or distant metastases following curative-intent therapy. Studies have reported local recurrence rates of 22% to 50%, distant recurrence rates of 48% to 78%, and simultaneous local and distant recurrence rates of 3% to 20%.1 Sites of distant recurrence include…